Daily News Podcast

Rivaroxaban data abound at ESC 2018

Publish date: August 28, 2018

 

New results from the ASCEND trial show that neither aspirin nor fish oil provides any net clinical benefit for primary cardiovascular prevention in patients with diabetes. Also today, rivaroxaban is no help for heart failure outcomes, VTE risk is unchanged by rivaroxaban taken after discharge, and the AAP cautions against marijuana use during pregnancy and breastfeeding. Subscribe to the MDedge Daily News wherever you get your podcasts.

Amazon Alexa
Apple Podcasts
Spotify

Recommended Reading

Mobile contraception app gets FDA approval
MDedge Endocrinology
Variation doesn’t mean quality when it comes to diet
MDedge Endocrinology
Medicare Advantage pushback
MDedge Endocrinology
Cardiovascular risk management supported for type 2 diabetes
MDedge Endocrinology
An epidemic of non-alcoholic fatty liver disease
MDedge Endocrinology
Sleepio app tied to reducing insomnia, depression
MDedge Endocrinology
5 digital HIPAA myths
MDedge Endocrinology
Screen for cervical cancer based on age, risk
MDedge Endocrinology
Is it time for PCPs to take over chronic HCV?
MDedge Endocrinology
Lorcaserin shows cardiovascular safety
MDedge Endocrinology